Microbicides for the prevention of sexually transmitted HIV infection

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 1, 2013, Pages 12-23

  Karim, Quarraisha Abdool ^a,b   Baxter, Cheryl ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

adherence; HIV prevention; microbicides; topical antiretrovirals; women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; DEXTRIN 2 SULFATE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LEVONORGESTREL; MARAVIROC; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; MIV 150; NONOXINOL 9; ORAL CONTRACEPTIVE AGENT; PRO 2000; SAVVY; TENOFOVIR; UNCLASSIFIED DRUG; ZINC ACETATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ARTICLE; BEHAVIORAL RESEARCH; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; EXPERIMENTAL MODEL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL ETHICS; MEN'S HEALTH; NONHUMAN; PATIENT COMPLIANCE; REPRODUCTIVE HEALTH; SEXUAL TRANSMISSION; TREATMENT PLANNING; VIRUS TRANSMISSION; WOMEN'S HEALTH;

EID: 84871956604     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.153     Document Type: Article

References (48)

1. Pettifor AE, Rees HV, Kleinschmidt I et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 19(14), 1525-1534 (2005). (Pubitemid 41400699)
2. Shisana O, Rehle T, Simbayi LC et al South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning tide Among Teenagers? HSRC Press, Cape Town, South Africa (2009).
3. Stone A, Harrison PF. Microbicides Y Ways Forward. Alliance for Microbicide Development, Silver Spring, MD, USA (2010).
4. Stein ZA. HIV prevention: The need for methods women can use. Am. J. Public Health 80(4), 460-462 (1990). (Pubitemid 20105954)
5. Richardson BA, Lavreys L, Martin HL Jr et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: A randomized clinical trial. Sex. Transm. Dis. 28(7), 394-400 (2001). (Pubitemid 32613682)
6. Kreiss J, Ngugi E, Holmes K et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268(4), 477-482 (1992).
7. Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339(8), 504-510 (1998). (Pubitemid 28384883)
8. Van Damme L, Ramjee G, Alary M et al.; COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 360(9338), 971-977 (2002). (Pubitemid 35284107)
9. Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria. PLoS One 3(1), e1474 (2008).
10. Peterson L, Nanda K, Opoku BK et al. SAVVY (C31G) gel for prevention of HIV infection in women: A Phase 3, doubleblind, randomized, placebo-controlled trial in Ghana. PLoS One 2(12), e1312 (2007).
11. Abdool Karim SS, Richardson BA, Ramjee G et al.; HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7), 957-966 (2011).
12. Lagenaur LA, Sanders-Beer BE, Brichacek B et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 4(6), 648-657 (2011).
13. Pearce-Pratt R, Phillips DM. Sulfated polysaccharides inhibit lymphocyte-toepithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 54(1), 173-182 (1996). (Pubitemid 126506813)
14. Saifuddin M, Doncel G, Tsai L et al. Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. Presented at: Microbicides 2008 conference. Delhi, India, 24-27 February 2008.
15. Rusconi S, Moonis M, Merrill DP et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40(1), 234-236 (1996). (Pubitemid 26020755)
16. Lewis M, Wagner W, Yalley-Ogunro J, Greenhouse J, Profy A. Efficacy of PRO 2000 gel in a macaque model for vaginal HIV transmission [Abstract A-191]. Presented at: Microbicides 2002 Conference. Antwerp, Belgium 12-15 May 2002).
17. Conrad. Investigator's brochure: Sodium cellulose sulfate 6% vaginal gel. (2006).
18. Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect. Dis. 5(6), 374-382 (2005). (Pubitemid 40779258)
19. Scordi-Bello IA, Mosoian A, He C et al. Candidate sulfonated and sulfated topical microbicides: Comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49(9), 3607-3615 (2005). (Pubitemid 41233007)
20. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 372(9654), 1977-1987 (2008).
21. Van Damme L, Govinden R, Mirembe FM et al.; CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463-472 (2008).
22. Doncel GF, Chandra N, Fichorova RN. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 37 (Suppl. 3), S174-S180 (2004). (Pubitemid 39435043)
23. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168-1174 (2010).
24. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 378(9787), 279-281 (2011).
25. Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306(5695), 485-487 (2004). (Pubitemid 39372448)
26. Harman S, Herrera C, Armanesco N et al. L'644, a cholesterol derivatized version of the gp41 fusion peptide C34, provides superior activity in preclinical microbicide assays [abstract 19]. Presented at: 2010 International Microbicides Conference. PA, USA 56(5), 2347-2356 (2010).
27. Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J. Acquir. Immune Defic. Syndr. 58(2), 207-210 (2011).
28. Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 374(9687), 416-422 (2009).
29. Voeller B. AIDS and heterosexual anal intercourse. Arch. Sex. Behav. 20(3), 233-276 (1991).
30. Gross M, Holte SE, Marmor M et al. Anal sex among HIV-seronegative women at high risk of HIV exposure. JAIDS 24, 393-398 (2000).
31. Halperin DT Heterosexual anal intercourse: Prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS 13(12), 717-730 (1999). (Pubitemid 30016740)
32. Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex. Transm. Infect. 85(6), 411-415 (2009).
33. Schwandt M, Morris C, Ferguson A, Ngugi E, Moses S. Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. Sex. Transm. Infect. 82(5), 392-396 (2006). (Pubitemid 44578293)
34. van Oosterhout JJ, Bodasing N, Kumwenda JJ et al. Evaluation of antiretroviral therapy results in a resourcepoor setting in Blantyre, Malawi. Trop. Med. Int. Health 10(5), 464-470 (2005). (Pubitemid 40712431)
35. Nachega JB, Stein DM, Lehman DA et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res. Hum. Retroviruses 20(10), 1053-1056 (2004). (Pubitemid 39392009)
36. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int. J. STD AIDS 16(1), 38-41 (2005). (Pubitemid 40193660)
37. Committee on the Methodological Challenges in HIV Prevention Trials. Methodological Challenges in Biomedical HIV Prevention Trials. Lagakos SW, Gable AR (Eds). The National Academy Press, DC, USA (2008).
38. Hendrix C, Minnis A, Guddera V et al. MTN-001: A Phase 2 Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations [Abstract 35LB]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. MA, USA 27 FebruaryY2 March 2011.
39. Anton PA, Cranston RD, Kashuba A et al. RMP-02/MTN-006: A Phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of Tenofovir 1% gel compared with oral Tenofovir Disoproxil Fumarate. AIDS Res. Hum. Retroviruses (2012).
40. Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J. Predicting the Impact of ART and PrEP with Overlapping Regimens on HIV Transmission and Drug Resistance in South Africa [abstract #98LB]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. MA, USA 27 FebruaryY2 March 2011.
41. Grant RM, Lama JR, Anderson PL et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587-2599 (2010).
42. Cassell MM, Halperin DT, Shelton JD, Stanton D Risk compensation: The Achilles' heel of innovations in HIV prevention? BMJ 332(7541), 605-607 (2006). (Pubitemid 44365764)
43. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS One 3(5), e2077 (2008).
44. Auvert B, Taljaard D, Rech D et al. Effect of the Orange Farm (South Africa) male circumcision roll-out (ANRS-12126) on the spread of HIV [abstract WELBC02]. Presented at: Sixth International AIDS Society Conference. Rome, Italy 19 July 2011.
45. Baeten JM, Donnell D, Ndase P et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367(5), 399-410 (2012).
46. Thigpen MC, Kebaabetswe PM, Paxton LA et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367(5), 423-434 (2012).
47. Cohen MS, Chen YQ, McCauley M et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6), 493-505 (2011).
48. Karim QA, Kharsany AB, Frohlich JA et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int. J. Epidemiol. 40(4), 922-930 (2011).